1. BMS Reports EMA’s Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Published: May 22, 2020 | Tags: bb2121, BMS ,CC-486, EMA, ide-cel Idecabtagene, Vicleucel MAA 2. Gilead Plans […]readmore
Tags : AveXis
Shots: The EC’s approval is based on P-III STR1VE-US and P-I START studies assessing the efficacy & safety of a one-time IV infusion of Zolgensma in symptomatic SMA Type 1 […]readmore
OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid […]readmore
Shots: The P-I/II STRONG study involves assessing AVXS-101 (IT) in patients with SMA Type 2 who have three copies of the SMN2 gene, and who can sit but cannot stand […]readmore
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
Shots: AveXis, a Novartis company purchases gene therapy manufacturing unit in Longmont, an addition to Durham facility of $115M investment, offering positions for 150 employees previously working at the site […]readmore
Shots: Novartis acquires AveXis, in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B The focus of […]readmore